Incidence and Predictors of Severe Adverse Drug Reactions among Patients on Antiretroviral Drugs in Harari Regional State, Eastern Ethiopia
Table 2
Baseline characteristics and follow-up measurements of patients on ART in Harari, Eastern Ethiopia, February 25 to March 25, 2022.
Characteristics (n = 449)
Exposed (n = 150)
Unexposed (n = 299)
CD4 count (cells/mm3)
<200
63 (42%)
24 (8%)
≥200
87 (58%)
275 (92%)
BMI
Underweight
62 (41.3%)
59 ((19.7%)
Normal
84 (56%)
226 (75.6%)
Overweight and obese
4 (2.7%)
14 (4.7%)
Nutritional status
Undernutrition
62 (41.3%)
58 (19.4%)
Normal
84 (56%)
227 (75.9%)
Overnutrition
4 (2.6%)
14 (4.6%)
WHO clinical stage
Stage I
176 (58.8%)
Stage II
123 (41.2%)
Stage III
128 (85.3%)
Stage IV
22 (14.7%)
Experience of TB infection
Yes
56 (37.3%)
12 (4%)
No
94 (62.7%)
287 (96%)
Experience of regimen change
Yes
73 (48.7%)
176 (58.8%)
No
77 (51.3%)
123 (41.2%)
Experience of other OIs other than TB
Yes
92 (61.3%)
84 (28.1%)
No
58 (38.7%)
215 (71.9%)
Functional status during ART initiation
Working
15 (10%)
257 (86%)
Ambulatory
106 (70.6%)
42 (14%)
Bedridden
29 (19.4%)
0
Baseline regimen
1c/1e
109 (72.6%)
215 (71.9%)
1J
33 (22%)
72 (24%)
Others¶
8 (5.4%)
12 (4.1%)
Experience of taking other medication¥
Yes
150 (100%)
217 (72.6%)
No
0
82 (21.4%)
Ever took CPT
Yes
82 (54.6%)
148 (49.5%)
No
68 (46.4%)
151 (50.1%)
Ever took anti-TB prophylaxis
Yes
49 (32.6%)
158 (52.8%)
No
101 (73.4%)
141 (47.2%)
Adherence status
Good
111 (76.6%)
246 (82.6%)
Fair
26 (18%)
44 (15.1%)
Poor
7 (5.4%)
7 (2.3%)
CD4 classification is based on the previous studies, 1c = AZT (zidovudine)+3TC + NVP (nevirapine), 1e = TDF + 3TC + EFV, 1J = TDF + 3TC + DTG (dolutegravir), ¶other regimens include 1d = AZT + 3TC + EFV, 1g = ABC (abacavir) + 3TC + EFV, 1f = TDF + 3TC + NVP, and 1h = ABC + 3TC + NVP, and ¥other medications include medications given for the PLWH other than anti-TB and CPT, therapeutic food, and any analgesics (antipain).
